Latent Tb Testing Market: Market Size & Forecast 2026

The latent tuberculosis infection testing market encompasses diagnostic tools used to detect TB bacteria in individuals who show no symptoms but may develop active disease later. Key testing methods include tuberculin skin tests (TST) and interferon-gamma release assays (IGRAs), which are blood-based tests offering greater specificity. The market benefits from widespread adoption in hospitals, diagnostic laboratories, and public health screening programs worldwide.

• •The market represents the largest segment of the broader TB diagnostics industry, exceeding 40% of total market value
• •Primary diagnostic technologies include tuberculin skin tests and interferon-gamma release assays (IGRAs)
• •Commercial market estimates range from approximately $1.9 billion to $2.8 billion across various industry analyses for 2025
• •Testing is conducted across hospitals, clinics, reference laboratories, and public health facilities

Global health organization recommendations for targeted LTBI screening among high-risk populations have significantly expanded testing volumes. The increasing prevalence of tuberculosis in developing regions, combined with immigration patterns from high-burden countries, drives demand in low-incidence nations. Additionally, technological improvements in IGRA testing have reduced turnaround times and improved accuracy compared to older skin test methods.

• •World Health Organization guidelines promoting systematic screening of at-risk populations including healthcare workers and close contacts
• •Rising HIV/AIDS prevalence globally increases demand for latent TB testing due to compromised immune systems
• •Advantages of IGRAs over skin tests, including single-visit administration and no cross-reactivity with BCG vaccination

The market is primarily segmented by test type, with IGRAs and tuberculin skin tests comprising the core diagnostic categories. North America leads in market value due to high healthcare spending and comprehensive screening programs, with the U.S. segment alone valued at nearly $500 million in 2025. Asia-Pacific represents the fastest-growing regional market due to high TB burden, improving healthcare infrastructure, and increasing government investment in disease control programs.

• •IGRAs are gaining market share over traditional skin tests due to superior specificity and convenience
• •The United States accounts for approximately $499.7 million in market value, growing at 3.8% annually
• •Asia-Pacific markets show strongest growth momentum driven by high disease prevalence and expanding healthcare access
• •Europe maintains significant market presence through government-sponsored screening initiatives

What are the recent trends and outlook?

Point-of-care testing solutions and molecular diagnostics are emerging as growth areas, potentially transforming how latent TB is detected in resource-limited settings. Integration of LTBI screening into primary care workflows and electronic medical records systems is expected to improve detection rates. Continued investments in research and development aim to create next-generation tests with improved sensitivity and reduced costs, supporting market expansion through 2030 and beyond.

• •Molecular and point-of-care testing technologies are gaining traction for decentralized screening programs
• •Public-private partnerships in high-burden countries are expected to expand testing access in underserved regions
• •Technological convergence with digital health platforms may improve patient tracking and treatment adherence
• •Market projections indicate sustained growth through 2030-2034 with cumulative value potentially exceeding $3 billion